Clinical studies on anti-obesity medications in Arab countries.

Most studies on anti-obesity medications in Arab countries are observational, with a focus on older drugs like liraglutide, and gastrointestinal side effects were reported in 32.2% of patients.

Summary and findings

This study aimed to summarize clinical studies on anti-obesity medications (AOMs) conducted in Arab countries, focusing on medication types, study designs, and reported efficacy and safety metrics. A total of 59 studies were included, primarily observational, with glucagon-like peptide-1 receptor agonists being the most investigated. Notably, gastrointestinal side effects were reported in 32.2% of patients across studies.

Abstract

<h4>Objectives</h4>To identify and summarize studies carried out in Arab countries on anti-obesity medications (AOMs), with a focus on the types of medications investigated, study designs, and the efficacy/effectiveness and safety metrics reported.<h4>Methods</h4>We carried out a comprehensive scoping review of primary studies examining the use of AOMs in adult Arab populations. Five databases (Medline, Embase, Cochrane Library, Index Medicus for the Eastern Mediterranean Region, and e-Marefa) were searched for English-language publications up to October 2024. Data extraction was carried out on study characteristics, participant demographics, interventions, and outcomes related to weight reduction, metabolic parameters, and side effects. The risk of bias (RoB) was assessed using the Newcastle-Ottawa scale for non-randomized studies and a modified RoB tool for randomized controlled trials.<h4>Results</h4>A total of 59 clinical studies published between 2014-2024 were included. The majority (89.8%) were observational in design. Most studies were carried out in Saudi Arabia (40.7%) and the United Arab Emirates (20.3%). Glucagon-like peptide-1 receptor agonists were investigated in 72.9% of the studies, with liraglutide being the most frequently studied agent (54.2%). The most commonly reported efficacy outcomes included changes in total body weight (45.8%), body mass index (39.0%), and the proportion of weight loss (28.8%). Gastrointestinal side effects were reported in 32.2% of patients across studies.<h4>Conclusion</h4>Despite the growing body of research on AOMs in Arab countries, most studies remain observational and focus primarily on earlier-generation agents. There is a need for randomized controlled trials to evaluate the efficacy and safety of newer AOMs, such as semaglutide and tirzepatide, within Arab populations to inform culturally and genetically tailored obesity management strategies.

Key findings

• Not reported in abstract.
• Not reported in abstract.
• Not reported in abstract.

Limitations

• Not reported in abstract.
• Not reported in abstract.

Elsewhere in the Cagrilintide (AM833) corpus